amg0103
Degenerative Disc Disease
AnGes, Inc.Phase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
9 Active assets in the Degenerative Disc Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NEPENTHE Brigham and Women's Hospital | Phase 4 | BB |
Oxycodone Brigham and Women's Hospital | Phase 4 | BB |
Pentoxifylline St Joseph University, Beirut, Lebanon | Phase 4 | BB |
IBUPROFEN St Joseph University, Beirut, Lebanon | Phase 4 | BB |
Rexlemestrocel-L Mesoblast, Ltd. | Phase 3 | BB |
View all 15 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →